1
|
Luo G, Jiang XJ, Chen L, Conway CM, Gulianello M, Kostich W, Keavy D, Signor LJ, Chen P, Davis C, Whiterock VJ, Schartman R, Widmann KA, Macor JE, Dubowchik GM. Calcitonin gene-related peptide (CGRP) receptor antagonists: Heterocyclic modification of a novel azepinone lead. Bioorg Med Chem Lett 2021; 43:128077. [PMID: 33932522 DOI: 10.1016/j.bmcl.2021.128077] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 04/19/2021] [Accepted: 04/25/2021] [Indexed: 11/19/2022]
Abstract
In our efforts to identify orally bioavailable CGRP receptor antagonists, we previously discovered a novel series of orally available azepinone derivatives that unfortunately also exhibited the unwanted property of potent time-dependent human CYP3A4 inhibition. Through heterocyclic replacement of the indazole ring, we discovered a series of heterocycle derivatives as high-affinity CGRP receptor antagonists. Some of them showed reasonable oral exposures, and the imidazolone derivatives that showed good oral exposure also exhibited substantially reduced time-dependent CYP3A4 inhibition. Several compounds showed strong in vivo efficacy in our marmoset facial blood flow assay with up to 87% inhibition of CGRP-induced activity. However, oral bioavailability generally remained low, emphasizing the challenges we and others encountered in discovering clinical development candidates for this difficult Class B GPCR target.
Collapse
Affiliation(s)
- Guanglin Luo
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Bristol Myers Squibb, Lawrenceville, NJ 08543, United States.
| | | | - Ling Chen
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Bristol Myers Squibb, Lawrenceville, NJ 08543, United States
| | - Charles M Conway
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Biohaven Pharmaceuticals Inc., New Haven, CT 06510, United States
| | - Michael Gulianello
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Sanofi, Framingham, MA 01701, United States
| | - Walter Kostich
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; National Multiple Sclerosis Society, New York, NY 10017, United States
| | - Deborah Keavy
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Medtronic, North Haven, CT 06473, United States
| | - Laura J Signor
- Bristol-Myers Squibb, Wallingford, CT 06492, United States
| | - Ping Chen
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Bristol Myers Squibb, Lawrenceville, NJ 08543, United States
| | - Carl Davis
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Amgen, Inc. Thousand Oaks, CA 91320, United States
| | | | - Richard Schartman
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Preformulation Solutions, LLC, North Ridgeville, OH 44039, United States
| | | | - John E Macor
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Sanofi, Waltham, MA 02451, United States
| | - Gene M Dubowchik
- Bristol-Myers Squibb, Wallingford, CT 06492, United States; Biohaven Pharmaceuticals Inc., New Haven, CT 06510, United States
| |
Collapse
|